•
May 31, 2020

Walgreens Q3 2020 Earnings Report

Financial performance was significantly impacted by the COVID-19 pandemic, but progress was accelerated on strategic priorities.

Key Takeaways

Walgreens Boots Alliance reported a challenging third quarter due to the COVID-19 pandemic, which significantly impacted sales and operating income. The company took actions to mitigate these impacts and accelerated investments in strategic priorities, increasing its annual cost savings target. While sales saw a slight increase, the company reported an operating loss due to impairment charges in Boots UK.

Sales increased 0.1 percent to $34.6 billion, up 1.2 percent on a constant currency basis.

Operating loss of $1.6 billion, compared to operating income of $1.2 billion a year ago, mainly due to the non-cash impairment charges of $2 billion in Boots UK.

Adjusted EPS decreased 43.8 percent from $1.47 to $0.83.

Company increased annual cost savings target from the Transformational Cost Management Program to in excess of $2.0 billion by fiscal 2022.

Total Revenue
$34.6B
Previous year: $34.6B
+0.1%
EPS
$0.83
Previous year: $1.47
-43.5%
Gross Profit
$5.96B
Previous year: $7.45B
-20.1%
Cash and Equivalents
$768M
Previous year: $768M
+0.0%
Free Cash Flow
$657M
Previous year: $1.57B
-58.1%
Total Assets
$86.4B
Previous year: $68.6B
+26.0%

Walgreens

Walgreens

Walgreens Revenue by Segment

Forward Guidance

The company introduced fiscal 2020 adjusted EPS guidance of $4.65 to $4.75, including estimated adverse COVID-19 impacts of $1.03 to $1.14 per share. This guidance assumes continued adverse impacts from COVID-19 in the fourth quarter.

Positive Outlook

  • More robust sales growth is expected in the Retail Pharmacy USA division.
  • Company increased annual cost savings target from the Transformational Cost Management Program to in excess of $2.0 billion by fiscal 2022
  • Company accelerated investments in strategic priorities, preparing for future growth
  • The company is seeing encouraging response from customers to its digital marketing initiatives
  • Walgreens total digitally initiated sales increased by 22.7 percent

Challenges Ahead

  • Company introduced fiscal 2020 adjusted EPS guidance of $4.65 to $4.75, including estimated adverse COVID-19 impacts of $1.03 to $1.14 per share
  • In the UK, retail conditions are expected to remain very depressed, despite gradual easing of restrictions.
  • retail margins are expected to remain compressed in comparison to fiscal 2019.
  • Operating loss of $1.6 billion, compared to operating income of $1.2 billion a year ago
  • Adjusted EPS decreased 43.8 percent from $1.47 to $0.83

Revenue & Expenses

Visualization of income flow from segment revenue to net income